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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 50, Revision 1 
(FGE.50Rev1): 
Consideration of pyrazine derivatives evaluated by JECFA (57th meeting) 
structurally related to pyrazine derivatives evaluated by EFSA in 
FGE.17Rev2 (2010)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 
2000 by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide 
whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. 
Since the previous version of FGE.50, new in vitro and in vivo genotoxicity data on 5-
methylquinoxaline [FL-no: 14.028] have been provided. The Panel concluded that these data allowed 
to roule out genotoxicity concerns for the substance. 5-Methylquinoxaline was then evaluated through 
a stepwise approach (the Procedure) that integrates information on structure-activity relationships, 
intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel concluded that the substance do not give rise to safety concerns at the levels of 
dietary intake, estimated on the basis of the MSDI approach. So in total, for all the 41 JECFA 
evaluated pyrazines derivatives [FL-no: 14.005, 14.006, 14.015, 14.017, 14.018, 14.019, 14.020, 
14.021, 14.022, 14.024, 14.025, 14.026, 14.027, 14.028, 14.031, 14.032, 14.034, 14.035, 14.037, 
14.043, 14.044, 14.049, 14.050, 14.053, 14.054, 14.055, 14.056, 14.062, 14.067, 14.069, 14.077, 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2010-00007, adopted on 25 November 2010. 
2  Panel members: Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean 
Claude Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, 
Detlef Wölfle. Correspondence: cef-unit@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: wishes to thank the members of the Working Groups on Flavourings for the preparation of this Opinion: Ulla 
Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, 
Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, Gerard Pascal, 
Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the preparatory work on this 
scientific Opinion. 
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14.082, 14.095, 14.096, 14.098, 14.100, 14.114, 14.121, 14.123, 14.142 and 14.144] evaluated in 
FGE.50, the Panel agrees with the JECFA conclusion, “No safety concern at estimated levels of intake 
as flavouring substances” based on the MSDI approach. Adequate specifications for the materials of 
commerce are available for all 41 flavouring substances. 
 
© European Food Safety Authority, 2011 
 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The present consideration concerns 41 pyrazine derivatives evaluated by the JECFA (57th meeting) 
and will be considered in relation to the EFSA evaluation of 21 pyrazine derivatives evaluated in the 
Flavouring Group Evaluation 17, Revision 2 (FGE.17Rev2). 
The Panel concluded that the 41 substances in the JECFA flavouring group of pyrazines are 
structurally related to the pyrazines evaluated by EFSA in FGE.17Rev2.  
In the previous version of the present Flavouring Group Evaluation (FGE), the Panel concluded that it 
could agree in the way the application of the Procedure has been performed by the JECFA for 40 out 
of the 41 pyrazines derivatives. For 5-methylquinoxaline [FL-no: 14.028], the Panel concluded that in 
line with the conclusions for quinoxaline and the two quinoxaline derivatives (quinoxaline [FL-no: 
14.147], 2-methylquinoxaline [FL-no: 14.139] and 2,3-dimethylquinoxaline [FL-no: 14.108]) in 
FGE.17Rev1, 5-methylquinoxaline should not be evaluated using the Procedure until adequate 
genotoxicity data become available. New genotoxicity data have now become available and based on 
these data the Panel concluded that the in vitro genotoxicity alert could be ruled out for 5-
methylquinoxaline [FL-no: 14.028] as no genotoxic potential at gene or chromosome level was 
indicated. 
For all 41 substances evaluated through the JECFA Procedure intake data are available for EU.  
For all 41 substances evaluated through the Procedure use levels are needed to calculate the 
mTAMDIs in order to identify those flavouring substances that need more refined exposure 
assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 41 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity are available for all 41 JECFA evaluated 
substances.  
For all the 41 JECFA-evaluated pyrazines [FL-no: 14.005, 14.006, 14.015, 14.017, 14.018, 14.019, 
14.020, 14.021, 14.022, 14.024, 14.025, 14.026, 14.027, 14.028, 14.031, 14.032, 14.034, 14.035, 
14.037, 14.043, 14.044, 14.049, 14.050, 14.053, 14.054, 14.055, 14.056, 14.062, 14.067, 14.069, 
14.077, 14.082, 14.095, 14.096, 14.098, 14.100, 14.114, 14.121, 14.123, 14.142 and 14.144] the Panel 
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agrees with the JECFA conclusion, “No safety concern at estimated levels of intake as flavouring 
substances” based on the MSDI approach. 
KEY WORDS 
Pyrazines, JECFA 57th meeting, pyrazine derivatives, quinoxaline derivatives, FGE.17Rev2. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 – 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted 
by Commission Decision 1999/217 EC (EC, 1999a) and its consecutive amendments. 
In addition, in letter of 1 April 2009 the Commission requested EFSA to carry out a re-evaluation of 
flavouring substances [FL-no: 14.028, 14.108 and 14.139] in accordance with Commission Regulation 
(EC) No 1565/2000: 
“The European Commission requests the European Food Safety Authority to carry out a risk 
assessment on 5-methylquinoxaline ([FL-no: 14.028]), 2,3-dimethylquinoxaline ([FL-no: 14.108]) and 
2-methylquinoxaline ([FL-no: 14.139]) in accordance with Commission Regulation (EC) No 
1565/2000, if possible by the end of the evaluation programme, if not within nine month from 
finalisation of that programme”.   
The deadline of the Terms of Reference was negotiated to 30 June 2010. 
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
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substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
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As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
In FGE.50, which contain a group of 41 flavouring substances consisting of pyrazine and pyrazine 
derivatives, the Panel concluded that for one of these substances, 5-methyl quinoxaline [FL-no: 
14.028], the Procedure should not be applied until adequate genotoxicity data become available. This 
conclusion was in line with the Panel conclusion for three other quinoxalines evaluated in 
FGE.17Rev1 (EFSA, 2008r).  
FGE Opinion 
adopted by 
EFSA 
Link No. of candidate 
substances 
FGE.50 February 
2007 
http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178692189146.htm 
41 
FGE.50Rev1 November 
2010 
 41 
 
Additional genotoxicity data have now become available for [FL-no: 14.028] and the present revision 
of FGE.50, FGE.50Rev1 includes the evaluation of these genotoxicity data submitted by the Industry 
(Flavour Industry, 2009a). 
Of the 41 flavouring substances considered by EFSA in FGE.50 no European production volumes 
were available for seven substances [FL-no: 14.025, 14.026, 14.034, 14.067, 14.069, 14.077 and 
14.121]. As no European production volumes were available no MSDI could be calculated for EU and 
accordingly the substances could not be considered by EFSA using the Procedure. In the course of 
2010, Industry provided EU production figures (EFFA, 2010a; EFFA, 2010c) for these seven 
substances together with similar data on approximately 100 other substances from 27 different 
FGEs. In order to avoid unnecessary delay, these substances were evaluated in a special FGE, 
FGE.96, in which EU production volumes / anticipated production volumens submitted on request 
by DC SANCO have been included in the evaluation (EFSA, 2010aj). The EU production 
volumes of these seven substances and the outcome of the evaluations have also been included in 
the current revision of FGE.50 (EFFA, 2010a; EFFA, 2010c). 
Finally, since the previous version of FGE.50 (EFFA, 2010a), missing information have been provided 
on the stereoisomeric composition for two substances [FL-no: 14.037 and 14.062], identity test for one 
substance [FL-no: 14.024], clarification of the specific gravity for three substances [FL-no: 14.019, 
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14.054 and 14.062] and composition of mixtures of positional isomers [FL-no: 14.006, 14.020, 
14.021, 14.025, 14.035, 14.050, 14.055, 14.067, 14.077, 14.100, 14.114 and 14.121]. 
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
The JECFA has evaluated a group of 41 flavouring substances consisting of pyrazine and pyrazine 
derivatives. 
1.1.2. EFSA Considerations 
The Panel concluded that all the 41 substances in the JECFA flavouring group of pyrazines are 
structurally related to the group of 21 pyrazines evaluated by EFSA in the Flavouring Group 
Evaluation 17, Revision 2 (FGE.17 Rev2). 
1.2. Isomers 
1.2.1. Status 
Two of the JECFA evaluated substances [FL-no: 14.037 and FL-no: 14.062] have a chiral centre. 
Further 12 substances consist of mixtures of positional isomers [FL-no: 14.006, 14.020, 14.021, 
14.025, 14.035, 14.050, 14.055, 14.067, 14.077, 14.100, 14.114 and 14.121]. 
1.2.2. EFSA Considerations 
Industry has informed that the two substances [FL-no: 14.037 and FL-no: 14.062] occur as a racemic 
mixture (EFFA, 2010a).  
Industry has informed about the composition of the mixture of positional isomers of the 12 JECFA 
evaluated substances [FL-no: 14.006, 14.020, 14.021, 14.025, 14.035, 14.050, 14.055, 14.067, 14.077, 
14.100, 14.114 and 14.121] (EFFA, 2010a). 
1.3. Specifications 
1.3.1. JECFA Status 
The JECFA specifications are available for all 41 substances (JECFA, 2001c). See Table 1. 
1.3.2. EFSA Considerations 
The available specifications are considered adequate for all 41 JECFA evaluated substances. 
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2. Intake Estimations 
2.1. JECFA Status 
For all 41 substances evaluated through the JECFA Procedure intake data are available for EU, see 
Table 3.1.   
2.2. EFSA Considerations 
No comments. 
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text Taken4 from the JECFA (JECFA, 2002a) 
In vitro 
2-Methylpyrazine [FL-no: 14.027], 2-ethylpyrazine [FL-no: 14.022], 2,3-dimethylpyrazine [FL-no: 
14.050], 2,5-dimethylpyrazine [FL-no: 14.020], 2,6-dimethylpyrazine [FL-no: 14.021], 2,3,5-
trimethylpyrazine [FL-no: 14.019], pyrazine [FL-no: 14.144]: These substances have been tested for 
their ability to cause reverse mutation, with uniformly negative results up to concentrations of 1000 
microgram/plate in various strains of Salmonella typhimurium with and without an exogenous 
metabolic activation system from rodent liver (Stich et al., 1980; Aeschbacher et al., 1989; Lee et al., 
1994a). In one of these studies, 2-methylpyrazine, 2-ethylpyrazine, 2,5-dimethylpyrazine, 2,6-
dimethylpyrazine, and pyrazine were also tested for their ability to cause mitotic crossover-gene 
conversion in Saccharomyces cerevisiae and chromosomal aberrations in Chinese hamster ovary cells 
(Stich et al., 1980). Surviving cells in cultures of stationary phase S. cerevisiae strain D5 showed an 
increase in the percentage of aberrant colonies at test concentrations of 3300–135 000 microgram/ml; 
however, no increase in the number of mitotic recombinants was observed among the aberrant 
colonies.  
Pyrazine and the other alkyl-substituted pyrazine derivatives that were tested induced significant 
percentages of chromosomal aberrations (breaks and exchanges) in metaphase plates in Chinese 
hamster ovary cells with and without metabolic activation at test concentrations of 2500–40000 
microgram/ml. However, these concentrations were two to four times lower than those that were 
cytotoxic, and no negative controls were used to allow a demonstration that a significant increase in 
the incidence of aberrations had actually occurred (Stich et al., 1980). 
(2, 5 or 6)-Methoxy-3-methylpyrazine [FL-no: 14.025]: A mixture of three isomers, (2, 5 or 6)-
methoxy-3-methylpyrazine, did not induce reverse mutation in S. typhimurium strain TA98, TA100, 
TA1535, TA1537, or TA1538 at concentrations of 3.6 mg/plate with and without metabolic activation 
(Wild et al., 1983).  
In vivo 
(2, 5 or 6)-Methoxy-3-methylpyrazine [FL-no: 14.025]: A test for Basc mutation was performed in 
Drosophila with a concentration of 10 mmol/L (140 microgram/ml), with no mutagenic effect (Wild et 
al., 1983). 
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the 
present FGE has been removed. 
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Male and female NMRI mice were treated once orally with (2, 5, or 6)-methoxy-3-methylpyrazine at a 
dose of 87, 174, or 248 mg/kg bw and killed, and bone-marrow smears were prepared 30 h after 
treatment. There was no increase in the frequency of micronuclei in polychromatic erythrocytes (Wild 
et al., 1983). 
Conclusion on genotoxicity 
The relevance of the positive results for pyrazine and certain alkylpyrazines in assays with S. 
cerevisiae and Chinese hamster ovary cells in vitro reported by Stich et al. (1980) is unclear. The 
studies were performed at high, nearly toxic concentrations of the weakly basic pyrazines, which may 
have altered cellular homeostasis. The results of studies of genotoxicity by Zajac-Kaye & Ts’o (Zajac-
Kaye & Ts’o, 1984), Brusick (Brusick, 1986), Bradley et al. (Bradley et al., 1987), and Heck et al. 
(Heck et al., 1989), for example, indicate that agents other than the pyrazines may have caused the 
observed results. The positive results in vitro reported by Stich et al. (Stich et al., 1980) were not 
corroborated by the results of studies conducted in vivo by Wild et al. (Wild et al., 1983) with (2, 5, or 
6)-methoxy-3-methylpyrazine [FL-no: 14.025]. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA see Table 2.1. 
3.2. Genotoxicity Studies - Text Taken5 from EFSA FGE.17Rev2 (EFSA, 2010h) 
Genotoxicity data were provided for three of the 20 candidate substances and for 11 of the 41 
supporting substances. The three candidate substances are quinoxaline [FL-no: 14.147] and its 
derivatives 2-methylquinoxaline [FL-no: 14.139] and 2,3-dimethylquinoxaline [FL-no: 14.108]. After 
finalisation of the previous version of this FGE (i.e. FGE.17, Revision 1), both in vitro and in vivo 
genotoxicity data have become available for the supporting substance 5-methylquinoxaline [FL-no: 
14.028]. This substance is a candidate flavouring substance in FGE.50. The Panel explored the option 
of using the genotoxicity data submitted for 5-methylquinoxaline [FL-no: 14.028] to support the 
evaluation of the genotoxic potential of the candidate quinoxaline derivatives in FGE.17.  
Genotoxicity data on Candidate substances 
In in vitro studies, quinoxaline [FL-no: 14.147], up to 10000 microgram/plate and 2,3-
dimethylquinoxaline [FL-no: 14.108], up to 2500 microgram/plate, with and without metabolic 
activation, did not cause reverse mutation in various strains of Salmonella typhimurium (See Table 
IV.4). Two studies on 2-methylquinoxaline [FL-no: 14.139] are available, one study with a positive, 
the other with negative result in the Ames test. However, quinoxaline [FL-no: 14.147] at 250 
microgram/ml culture medium and with metabolic activation was found to induce TFT-mutants in the 
mouse lymphoma mutagenesis assay (L5178Y TK+/- cells). This study was conducted in accordance 
with the OECD guideline 476 and therefore considered valid. 
No adequate in vivo studies on genotoxicity of the substances are available. A study of the potential of 
quinoxaline [FL-no: 14.147] to induce sperm head abnormalities (Topham, 1980) did not address a 
genetic endpoint and the Panel considered it could not be used for evaluation of genotoxicity of this 
substance. 
Genotoxicity data on Supporting substances  
Substituted pyrazines  
 
                                                     
 
5 The text is taken verbatim from the indicated reference source, but text related to substances not included in the 
present FGE has been removed. 
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In vitro, 2-methylpyrazine [FL-no: 14.027], ethylpyrazine [FL-no: 14.022], 2,3-dimethylpyrazine [FL-
no: 14.050], 2,5-dimethylpyrazine [FL-no: 14.020], 2,3-diethylpyrazine [FL-no: 14.005], 2,6-
dimethylpyrazine [FL-no: 14.021], 2,3,5-trimethylpyrazine [FL-no: 14.019], pyrazine [FL-no: 14.144] 
and (2, 5 or 6)-methoxy-3-methylpyrazine [FL-no: 14.025] were tested for their ability to cause 
reverse mutation in various strains of S. typhimurium and consistently revealed negative results with 
and without metabolic activation (Table 2.2).  
In one of these studies, 2-methylpyrazine, ethylpyrazine, 2,5-dimethylpyrazine, 2,6-dimethylpyrazine, 
and pyrazine were also tested for their potential to cause genotoxicity in Saccharomyces cerevisiae 
and chromosomal aberrations in Chinese hamster ovary cells (Table 2.2) (Stich et al., 1980). This 
study has strong limitations for the following reasons. The positive results were observed only in a 
narrow range of exceedingly high and toxic concentrations. In the case of chromosome aberrations, the 
concentration used exceeded the maximum level (5 mg/ml) recommended by OECD. It has been 
shown (Galloway, 2000) that in vitro chromosome breaking can occur secondary to toxicity and/or 
changed physiological conditions (e.g., pH, osmolarity) with compounds not able to react with DNA 
and negative in the Ames test and in vivo. The S.cerevisiae D5 assay for induction of "aberrant 
colonies" is not routinely used and has not been validated at international level due to the uncertainty 
on the various effects involved. Thus, the positive results reported by Stich et al. (Stich et al., 1980) 
are considered of limited value and not relevant for hazard and risk assessment. Furthermore, pyrazine 
was found negative in a wide range of concentrations both in the Salmonella assay and in the mouse 
lymphoma TK assay (Fung et al., 1988). 
Quinoxalines 
5-Methylquinoxaline [FL-no: 14.028] was examined for its mutagenic potential in Salmonella 
typhimurium strains TA100, TA1535, TA98 and TA1537, as well as in Escherichia coli strain WP2 
uvrA. The study was conducted according to GLP and was in compliance with OECD Guideline 471. 
No evidence of mutagenicity was found with or without S9 metabolic activation at concentrations up 
to 5,000 µg/plate (Ogura & Wakamatsu, 2004).  
5-methylquinoxaline was examined for its potential to induce structural chromosome aberrations in 
mammalian cells. The study was conducted according to GLP and was in compliance with OECD 
Guideline 473. The test system used was a subculture of Chinese hamster lung-derived CHL/IU cells 
that were exposed to the test material at concentrations of 320, 480 and 720 µg/mL without S9 mix, 
and 72.0, 228 and 720 µg/mL with S9 mix. The percentage of “cell productivity” (the cell number was 
measured and expressed as relative growth rate compared to negative control) was reported as a 
parameter for cytotoxicity. The Panel considered that 5-methylquinoxaline was found to induce 
chromosomal aberrations in cultured mammalian cells in the presence of metabolic activation. 
Additionally, an increased frequency of polyploid cells up to 12.5 % of the middle dose compared to 0 
% in the control was observed in the presence and absence of metabolic activation at concentrations 
which induced only low cytotoxicity (Ajimu & Kawaguchi, 2004a) 
In vivo data are available for two one of the supporting substances only, (2, 5 or 6)-Methoxy-3-
methylpyrazine [FL-no: 14.025] and 5-methylquinoxaline [FL-no: 14.028].  
5-Methylquinoxaline [FL-no: 14.028] was examined for its potential to induce micronucleated 
polychromatic erythrocytes (MNPCEs) in the bone marrow. The test material was administered daily 
(gavage) for two consecutive days to seven week old and six week old male SPF ICR (Crj:CD-1) mice 
at dosages of 125, 250 and 500 mg/kg/day (6 animals/dose). Microscopic examination of femoral bone 
marrow cells was conducted randomly from 5 animals. Two thousand polychromatic erythrocytes 
(PCE) per animal were analyzed microscopically (x1000), and the number of micronucleated 
polychromatic erythrocytes (MNCPE) was recorded. In order to evaluate the PCE/NCE ratio, the 
number of PCEs out of 200 total erythrocytes (PCEs plus NCEs) was recorded. The test was 
considered positive if the MNPCE frequencies in one or more treatment groups were significantly 
higher than that in the negative control groups. No significant increase of micronucleated 
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polychromatic erythrocyte frequency was observed in these treatment groups compared with the 
negative control group. The PCE/NCE ratio was not changed (Ajimu & Kawaguchi, 2004b). Based on 
the PCE/NCE ratio there is no indication that the substance reached the bone marrow, however, the 
Panel noted that the high dose was the maximum tolerated dose since clinical signs of toxicity have 
been observed after oral intake. Additionally, a doubling of this dose was lethal for two out of six 
animals in a preliminary test. Thus, the Panel considered it reasonable to assume that the substance 
was systemically available and reached the bone marrow. 
For (2, 5 or 6)-methoxy-3-methylpyrazine [FL-no: 14.025] a test for Basc mutation was performed in 
Drosophila with a concentration of 10 mmol/L (140 microgram/ml) in the solutions/emulsions fed to 
the flies, with no mutagenic effect (Table 2.3). Secondly, male and female NMRI mice were treated 
once orally with 87, 174 or 248 mg/kg bw, bone-marrow smears were prepared only at one sampling 
time (at 30 hours) after treatment. There was no increase in the frequency of micronuclei in 
polychromatic erythrocytes (Table 2.3). The PCE/NCE ratio was not reported and thus, it is not clear 
if the test substance reached the bone marrow. However from this study, there is no evidence of 
genotoxic potential. 
Conclusion on genotoxicity 
The available data indicate that apparently there is no simple structure-activity relationship for the 
genotoxicity of quinoxalines, because the profile of genotoxic events in vitro differs for the various 
congeners (point mutations for [FL no: 14.139] and [FL-no: 14.147] vs chromosomal aberrations for 
[FL no: 14.028]). Therefore these compounds are to be evaluated based on substance-specific data for 
each individual quinoxaline derivative. 
In vitro data indicate a genotoxic potential for quinoxaline [FL-no: 14.147] and 2-methylquinoxaline 
[FL-no: 14.139], for which no in vivo data are available. Therefore, for these two substances the 
Procedure cannot be applied until adequate genotoxicity data become available.  
Conversely, 2,3-dimethylquinoxaline [FL-no: 14.108] is not considered genotoxic in vitro and hence 
can be evaluated through the Procedure (three negative bacterial reverse gene mutation assays which, 
although limited, consistently indicate lack of genotoxicity). 
The Panel concluded that no genotoxic potential is indicated for 19 candidate substances, including 
2,3-dimethylquinoxaline [FL-no: 14.108]. For these 19 substances, the available data do not preclude 
their evaluation through the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA see Table 2.2 and 2.3. 
3.3. EFSA Considerations 
The Panel considered that no genotoxic potential at gene or chromosome level is indicated for this 
group of flavourings. 
4. Application of the Procedure 
4.1. Application of the Procedure to Pyrazine and 40 Derivatives by JECFA (JECFA, 
2002b) 
According to the JECFA 32 of the substances belong to structural class II and nine to structural class 
III using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
Flavouring Group Evaluation 50, Revision 1
 
 
13 EFSA Journal 2011;9(5):1921 
The JECFA concluded all 41 pyrazines at step A3 in the JECFA Procedure – i.e. the substances are 
expected to be metabolised to innocuous products (step 2) and the intakes for all substances are below 
the thresholds for their structural classes II and III (step A3).  
In conclusion, the JECFA evaluated all 41 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substance based on the MSDI approach. 
The evaluations of the 41 substances are summarised in Table 3.1: Summary of Safety Evaluation of 
Pyrazine and 40 Derivatives (JECFA, 2003a). 
4.2. Application of the Procedure to 21 Pyrazine Derivatives by EFSA (FGE.17Rev2) 
(EFSA, 2010h) 
In the previous version of FGE.17, FGE.17Rev1, it was found that two of the candidate substances, 
quinoxaline [FL-no: 14.147] and 2-methylquinoxaline [FL-no: 14.139] showed possible genotoxic 
potential in vitro. Therefore, the Panel decided that the Procedure could not be applied to these two 
candidate substances nor for the structurally related 2,3-dimethylquinoxaline [FL-no: 14.108] until 
adequate genotoxicity data become available.  
Additional genotoxicity data have now become available for the structurally related 5-
methylquinoxaline [FL-no: 14.028] and in the present FGE these genotoxicity data submitted by the 
Industry (Flavour Industry, 2009a) have been evaluated. The available data indicate that there is no 
apparent structure-activity relationship for the genotoxicity of quinoxalines (Hashimoto et al., 1979): 
thus these compounds are to be considered individually. 2,3-Dimethylquinoxaline [FL-no: 14.108] is 
not genotoxic in vitro and can be evaluated through the Procedure; conversely, in vitro data indicate a 
genotoxic potential for quinoxaline [FL-no: 14.147] and 2-methylquinoxaline [FL-no: 14.139], for 
which no in vivo data are available. Therefore, for these two substances the Procedure cannot be 
applied until adequate genotoxicity data become available. 
Furthermore, the candidate substance, 2,5 or 6-methoxy-3-ethylpyrazine [FL-no: 14.051] no European 
production figures were available and consequently no European exposure estimates could be 
calculated. Accordingly, the safety in use could not be assessed using the Procedure for this substance. 
Of the 18 candidate substances which are evaluated using the Procedure, 16 are classified into 
structural class II and two substances into structural class III using the decision tree approach 
presented by Cramer et al. (Cramer et al., 1978). 
Sixteen of the 18 substances were concluded at step A3 – i.e. the substances are expected to be 
metabolised to innocuous products (step 2) and the estimated daily intakes are below the threshold for 
the structural class (step A3). Two candidate substances cannot be anticipated to be metabolised to 
innocuous products [FL-no: 14.122 and 14.052]. Therefore these two substances are evaluated along 
the B-side of the Procedure scheme. 
For these substance the intake is below the threshold for the structural class (step B3). For 2-isopropyl-
3-methyl thiopyrazine [FL-no: 14.122] a NOAEL exists to provide an adequate margin of safety to the 
estimated level of intake as flavouring substance (step B4). For one substance, isopropenylpyrazine 
[FL-no: 14.052] or for any relevant supporting substances no valid toxicity study from which a 
NOAEL could be established was available. Therefore, the Panel concluded that additional toxicity 
data are needed for this substance. 
In conclusion the Panel considered that the 17 of the 18 substances evaluated through the Procedure 
were of no safety concern at the estimated levels of intake based on the MSDI approach. 
The stepwise evaluations of the 18 substances are summarised in Table 3.2: Summary of Safety 
Evaluation Applying the Procedure (EFSA, 2010h). 
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4.3. EFSA Considerations 
In the previous version of the present FGE, FGE50, the Panel concluded that they could agree in the 
way the application of the Procedure has been performed by the JECFA for 40 out of the 41 pyrazines 
derivatives. For 5-methylquinoxaline [FL-no: 14.028], the Panel concluded that in line with the 
conclusions for quinoxaline and the quinoxaline derivatives in FGE17.Rev1, 5-methylquinoxaline 
should not be evaluated using the Procedure until adequate genotoxicity data become available. 
Furthermore, for seven substances [FL-no: 14.025, 14.026, 14.034, 14.067, 14.069, 14.077 and 
14.121], the evaluation could not be finalised due to missing EU production volumes. 
New data on in vitro and in vivo genotoxicity for 5-methylquinoxaline [FL-no: 14.028] provided by 
Industry, were considered in this revision. Based on these data the Panel concluded that the in vitro 
genotoxicity alert could be ruled out for 5-methylquinoxaline [FL-no: 14.028] in FGE.50 as no 
genotoxic potential at gene or chromosome level was indicated. 
Accordingly, the Panel therefore considered that no genotoxic potential is indicated for this group of 
41 pyrazine derivatives. 
The JECFA concluded at their 57th meeting that 5-methylquinoxaline [FL-no: 14.028] would be 
metabolised to innocuous products. The Panel agrees with the JECFA conclusion “no safety concern 
at estimated levels of intake as flavouring substances” based on the MSDI approach. 
Based on newly submitted EU production volumes for the seven JECFA evaluated substances [FL-no: 
14.025, 14.026, 14.034, 14.067, 14.069, 14.077 and 14.121] the MSDIs range from 0.0012 to 2.2 
microgram/capita/day, which are all below the threshold for their respective structural class.  
For all seven substances the Panel concluded at step A3 that these substances would be of no safety 
concern at their estimated level of intake based on the MSDI approach (EFSA, 2010aj). 
5. Conclusion 
The Panel concluded that the 41 substances in the JECFA flavouring group of pyrazines are 
structurally related to the pyrazines evaluated by EFSA in the Flavouring Group Evaluation 17 
(FGE.17Rev2).  
In the previous version of the present FGE, FGE50, the Panel concluded that it could agree in the way 
the application of the Procedure has been performed by the JECFA for 40 out of the 41 pyrazines 
derivatives. For 5-methylquinoxaline [FL-no: 14.028], the Panel concluded that in line with the 
conclusions for quinoxaline and the two quinoxaline derivatives (quinoxaline [FL-no: 14.147], 2-
methylquinoxaline [FL-no: 14.139] and 2,3-dimethylquinoxaline [FL-no: 14.108]) in FGE17.Rev1, 5-
methylquinoxaline should not be evaluated using the Procedure until adequate genotoxicity data 
become available. New genotoxicity data have now become available and based on these data the 
Panel concluded that the in vitro genotoxicity alert could be ruled out for 5-methylquinoxaline [FL-no: 
14.028] as no genotoxic potential at gene or chromosome level was indicated. 
For all 41 substances evaluated through the JECFA Procedure intake data are available for EU.   
For all 41 substances evaluated through the Procedure use levels are needed to calculate the 
mTAMDIs in order to identify those flavouring substances that need more refined exposure 
assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 41 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity are available for all the 41 JECFA 
evaluated substances.  
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For all the 41 JECFA evaluated pyrazines [FL-no: 14.005, 14.006, 14.015, 14.017, 14.018, 14.019, 
14.020, 14.021, 14.022, 14.024, 14.025, 14.026, 14.027, 14.028, 14.031, 14.032, 14.034, 14.035, 
14.037, 14.043, 14.044, 14.049, 14.050, 14.053, 14.054, 14.055, 14.056, 14.062, 14.067, 14.069, 
14.077, 14.082, 14.095, 14.096, 14.098, 14.100, 14.114, 14.121, 14.123, 14.142 and 14.144] the Panel 
agrees with the JECFA conclusion, “No safety concern at estimated levels of intake as flavouring 
substances” based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2001c) 
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Pyrazines (JECFA, 2001c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
14.005 
771 
2,3-Diethylpyrazine N
N  
3136 
534 
15707-24-1 
Liquid 
C8H12N2 
136.20 
Soluble 
Miscible 
180 
 
IR 
97 % 
1.492-1.509 
0.956-0.976 
 
 
14.006 
768 
2-Ethyl-3-methylpyrazine N
N  
3155 
548 
15707-23-0 
Liquid 
C7H10N2 
122.17 
Soluble 
Miscible 
57 (13 hPa) 
 
IR 
97 % 
1.499-1.509 
0.972-0.993 
Mixture of positional 
isomers (2,3-; 2,5- and 2,6-
isomers), 2,3- (75-85 %); 
2,5- (15-25 %) and 2,6-
isomers (1-2 %) (sum 97%) 
(EFFA, 2010a). 
14.015 
952 
5,6,7,8-Tetrahydroquinoxaline N
N  
3321 
721 
34413-35-9 
Solid 
C8H10N2 
134.18 
Moderately soluble 
Soluble 
85 (4 hPa) 
29-30 
IR 
98 % 
n.a. 
n.a. 
 
 
14.017 
770 
2-Ethyl-5-methylpyrazine N
N  
3154 
728 
13360-64-0 
Liquid 
C7H10N2 
122.17 
Soluble 
Miscible 
79 (88 hPa) 
 
IR 
95 % 
1.491-1.501 
0.960-0.970 
 
 
14.018 
780 
2,3,5,6-Tetramethylpyrazine 
N
N
 
3237 
734 
1124-11-4 
Solid 
C8H12N2 
136.20 
Slightly soluble 
Very soluble 
190 
85-90 
IR 
95 % 
n.a. 
n.a. 
 
 
14.019 
774 
2,3,5-Trimethylpyrazine N
N  
3244 
735 
14667-55-1 
Liquid 
C7H10N2 
122.17 
Soluble 
Miscible 
171 
 
IR 
98 % 
1.500-1.509 
0.967-0.987 
Specific gravity: depending 
on the quality and the 
producer, the SG ranges 
from: 0.967-0.987 (EFFA, 
2010a). 
14.020 
766 
2,5-Dimethylpyrazine N
N  
3272 
2210 
123-32-0 
Liquid 
C6H8N2 
108.14 
Soluble 
Miscible 
155 
 
IR 
98 % 
1.497-1.503 
0.982-1.000 
Mixture of positional 
isomers (2,5- and 2,6-
isomers), 2,5- (45-65 %) and 
2,6-isomers (35-55 %) (sum 
98 %) (EFFA, 2010a).  
14.021 
767 
2,6-Dimethylpyrazine N
N  
3273 
2211 
108-50-9 
Solid 
C6H8N2 
108.14 
Soluble 
Very soluble 
154 
48 
IR 
98 % 
n.a. 
n.a. 
Mixture of positional 
isomers (2,5- and 2,6-
isomers), 2,5- (35-55 %) and 
2,6-isomers (45-65 %) (sum 
98 %) (EFFA, 2010a). 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Pyrazines (JECFA, 2001c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
14.022 
762 
Ethylpyrazine 
N
N
 
3281 
2213 
13925-00-3 
Liquid 
C6H8N2 
108.14 
Soluble 
Miscible 
152 
 
IR 
98 % 
1.493-1.508 
0.981-1.000 
 
 
14.024 
776 
2-Ethyl-3,5-dimethylpyrazine N
N  
3150 
2245 
13925-07-0 
Liquid 
C8H12N2 
136.20 
Soluble 
Miscible 
180 
 
IR MS 
95 % 
1.496-1.502 
0.952-0.961 
 
 
14.025 
788 
2,5 or 6-Methoxy-3-
methylpyrazine 
N
N O N
N
O
N
N
O
2-Methoxy-3-methylpyrazine 6-Methoxy-3-methylpyrazine
5-Methoxy-3-methylpyrazine
3183 
2266 
63450-30-6 
Liquid 
C6H8ON2 
124.14 
Soluble 
Miscible 
80-85 (13 hPa) 
 
IR 
97 % 
1.505-1.510 
1.060-1.090 
 
Mixture of positional 
isomers (2/5/6-MeO-3-Me), 
2-3- (75-85 %); 6-3- (15-25 
%) and 5-3- isomers (1-2 %) 
(sum 97 %) (EFFA, 2010a). 
14.026 
772 
2-Isopropyl-5-methylpyrazine 
N
N
3554 
2268 
13925-05-8 
Liquid 
C8H12N2 
136.20 
Soluble 
Miscible 
190 
 
NMR 
97 % 
1.492-1.498 
0.977-0.984 
 
 
14.027 
761 
2-Methylpyrazine N
N  
3309 
2270 
109-08-0 
Liquid 
C5H6N2 
94.12 
Soluble 
Miscible 
137 
 
IR 
98 % 
1.501-1.509 
1.007-1.033 
 
 
14.028 
798 
5-Methylquinoxaline 
N
N
3203 
2271 
13708-12-8 
Liquid 
C9H8N2 
144.18 
Freely soluble 
Very soluble 
120 (20 hPa) 
20 
IR 
98 % 
1.616-1.624 
1.102-1.128 
 
 
14.031 
795 
Pyrazineethanethiol 
N
N SH
 
3230 
2285 
35250-53-4 
Liquid 
C6H8N2S 
140.21 
Soluble 
Miscible 
105-110 (26hPa) 
 
IR 
97 % 
1.553-1.570 
1.147-1.157 
 
 
14.032 
784 
Acetylpyrazine 
N
N
O 3126 
2286 
22047-25-2 
Solid 
C6H6ON2 
122.13 
Slightly soluble 
Moderately soluble 
188 
74-80 
IR 
99 % 
n.a. 
n.a. 
 
 
14.034 
796 
Pyrazinyl methyl sulfide 
N
N S
 
3231 
2288 
21948-70-9 
Solid 
C5H6N2S 
126.18 
Soluble 
Very soluble 
75 (7 hPa) 
42-47 
IR 
99 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Pyrazines (JECFA, 2001c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
14.035 
797 
2-Methyl-3,5 or 6-
methylthiopyrazine 
N
N
N
N
N
N
S S
S
3-Methylthio-2-methylpyrazine 5-Methylthio-2-methylpyrazine
6-Methylthio-2-methylpyrazine
3208 
2290 
67952-65-2 
Liquid 
C6H8N2S 
140.21 
Miscible 
Miscible 
85-87 (13 hPa) 
 
IR 
99 % 
1.570-1.590 
1.133-1.153 
Mixture of positional 
isomers (2-Me-3/5/6-
Methylthio), 2-methyl-3-
methylthio-isomer (75-85 
%); main SCs: 2-5-isomer 
(15-25 %) and 2-6-isomer 
(1-2 %) (EFFA, 2010a). 
14.037 
781 
6,7-Dihydro-5-methyl-5H-
cyclopentapyrazine 
N
N
 
3306 
2314 
23747-48-0 
Liquid 
C8H10N2 
134.18 
Slightly soluble 
Miscible 
200 
 
IR 
97 % 
1.525-1.535 
1.048-1.059 
 
Racemate (EFFA, 2010a) 
 
14.043 
792 
2-Isobutyl-3-methoxypyrazine 
N
N
O
3132 
11338 
24683-00-9 
Liquid 
C9H14ON2 
166.22 
Soluble 
Miscible 
60 (3 hPa) 
 
IR 
95 % 
1.487-1.497 
0.983-1.003 
 
 
14.044 
773 
2-Isobutyl-3-methylpyrazine N
N  
3133 
 
13925-06-9 
Liquid 
C9H14N2 
150.22 
Soluble 
Miscible 
199 
 
IR 
98 % 
1.488-1.498 
0.936-0.942 
 
 
14.049 
785 
2-Acetyl-3-ethylpyrazine 
N
N
O 3250 
11293 
32974-92-8 
Liquid 
C8H10ON2 
150.18 
Soluble 
Miscible 
220 
 
IR 
98 % 
1.509-1.520 
1.068-1.079 
 
 
14.050 
765 
2,3-Dimethylpyrazine N
N  
3271 
11323 
5910-89-4 
Liquid 
C6H8N2 
108.14 
Soluble 
Miscible 
156 
 
IR 
95 % 
1.501-1.510 
0.997-1.030 
Mixture of positional 
isomers (2,3-; 2,5- and 2,6-
isomers), 2,3- (70-85 %); 
2,5- (10-25 %) and 2,6-
isomers (1-2 %) (sum 95 %) 
(EFFA, 2010a). 
14.053 
794 
Mercaptomethylpyrazine N
N
SH
 
3299 
11502 
59021-02-2 
Liquid 
C5H6N2S 
126.18 
Soluble 
Miscible 
94 (13 hPa) 
 
IR 
98 % 
1.548-1.560 
1.148-1.156 
 
 
14.054 
787 
Methoxypyrazine N
N
O
 
3302 
11347 
3149-28-8 
Liquid 
C5H6ON2 
110.12 
Miscible 
Miscible 
61-62 (38 hPa) 
 
IR 
99 % 
1.492-1.510 
1.110-1.140 
Specific gravity: depending 
on the quality and the 
producer, the SG ranges 
from: 1.110-1.140 (EFFA, 
2010a). 
14.055 
786 
2-Acetyl-3,5-dimethylpyrazine 
N
N
O
N
N
O
 
3327 
11294 
54300-08-2 
Liquid 
C8H10ON2 
150.18 
Soluble 
Miscible 
70 (9 hPa) 
 
IR 
97 % 
1.510-1.520 
1.070-1.075 
Mixture of positional 
isomers (2-Acetyl-3,5/6-
dimethyl), 3,5-dimethyl (65-
70 %) and 3,6-dimethyl (25-
30 %) isomers (sum 95 %) 
(EFFA, 2010a). 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Pyrazines (JECFA, 2001c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
14.056 
777 
2,3-Diethyl-5-methylpyrazine 
N
N
 
3336 
11303 
18138-04-0 
Liquid 
C9H14N2 
150.22 
Moderately soluble 
Miscible 
203 
 
IR 
98 % 
1.493-1.505 
0.938-0.957 
 
 
14.062 
791 
2-(sec-Butyl)-3-methoxypyrazine N
N
O
 
3433 
11300 
24168-70-5 
Liquid 
C9H14ON2 
166.22 
Soluble 
Miscible 
50 (1 hPa) 
 
IR 
99 % 
1.478-1.498 
0.976-1.002 
Racemate (EFFA, 2010a). 
Specific gravity: depending 
on the quality and the 
producer, the SG ranges 
from: 0.976-1.002 (EFFA, 
2010a).  
14.067 
793 
2-Methyl-3,5 or 6-
ethoxypyrazine 
N
N
N
N
N
N
O O
O
2-Methyl-3-ethoxypyrazine 2-Methyl-5-ethoxypyrazine
2-Methyl-6-ethoxypyrazine  
3569 
11921 
32737-14-7 
Liquid 
C7H10ON2 
138.17 
Soluble 
Miscible 
175-176 
 
IR 
97 % 
1.493-1.497 
1.034-1.041 
Mixture of positional 
isomers (2-Methyl-3/5/6-
ethoxy-), 2-methyl-3-
ethoxypyrazine (75-85 %), 
2-methyl-5-ethoxypyrazine 
(15-25 %) and 2-methyl-6-
ethoxypyrazine (1-2 %) 
(sum 97 %) (EFFA, 2010a). 
14.069 
783 
Cyclohexylmethylpyrazine N
N  
3631 
 
28217-92-7 
Liquid 
C11H16N2 
176.26 
Slightly soluble 
Miscible 
100 (5 hPa) 
 
NMR 
97 % 
1.515-1.520 
1.003-1.009 
 
 
14.077 
789 
2-Ethyl-(3,5 or 6)-
methoxypyrazine (85%) and 2-
Methyl-(3,5 or 6)-
methoxypyrazine (13%) 
N
N
O
N
N
O
(85%) (15%)  
3280 
11329 
 
Liquid 
 
 
Soluble 
Miscible 
80-95 (13 hPa) 
 
IR 
99 % 
1.497-1.505 
1.036-1.052 
Mixture of positional 
isomers (2-Ethyl/Methyl-
(3/5/6)-methoxypyrazine: 2-
Ethyl form (85 %) & 2-
Methyl form (13 %), 2-3- 
(75-85 %); 2-5- (15-25 %) 
and 2-6- ethyl or methyl (1-
2 %) (EFFA, 2010a). 
 
14.082 
950 
2-Acetyl-3-methylpyrazine 
N
N
O 3964 
11296 
23787-80-6 
Liquid 
C7H8ON2 
136.15 
Soluble 
Miscible 
90 (26 hPa) 
 
IR 
98 % 
1.521-1.523 
1.105-1.114 
 
 
14.095 
779 
3,5-Diethyl-2-methylpyrazine 
N
N
 
3916 
11305 
18138-05-1 
Liquid 
C9H14N2 
150.22 
Slightly soluble 
Miscible 
95 (18 hPa) 
 
NMR 
97 % 
1.492-1.502 
0.944-0.954 
 
 
14.096 
778 
2,5-Diethyl-3-methylpyrazine 
N
N
 
3915 
11304 
32736-91-7 
Liquid 
C9H14N2 
150.22 
Moderately soluble 
Miscible 
95 (18 hPa) 
 
NMR 
97 % 
1.4922-
1.5022 
0.944-0.954 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Pyrazines (JECFA, 2001c) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
14.098 
782 
6,7-Dihydro-2,3-dimethyl-5H-
cyclopentapyrazine 
N
N
 
3917 
11309 
38917-62-3 
Solid 
C9H12N2 
148.21 
Slightly soluble 
Very soluble 
66 (3 hPa) 
25-27 
NMR 
97 % 
n.a. 
n.a. 
CASrn in Register refers to 
6,7-dihydro-3,5-dimethyl-
5H-cyclopentapyrazine. 
CASrn to be changed. 
14.100 
775 
3,(5- or 6-)-Dimethyl-2-
ethylpyrazine 
N
N
N
N
2-Ethyl-3,6-dimethylpyrazine2-Ethyl-3,5-dimethylpyrazine  
3149 
727 
55031-15-7 
Liquid 
C8H12N2 
136.2 
Soluble 
Miscible 
180 
 
IR NMR 
95 % 
1.496-1.506 
0.950-0.980 
Mixture of positional 
isomers (2-Ethyl-3,5/6-
dimethyl-), 2-ethyl-3,5-
dimethylpyrazine (50-57 
%); 2-ethyl-3,6-
dimethylpyrazine (43-50 %) 
(EFFA, 2010a). 
14.114 
769 
2-Ethyl-6-methylpyrazine 
N
N
 
3919 
11331 
13925-03-6 
Liquid 
C7H10N2 
122.17 
Soluble 
Miscible 
80 (65 hPa) 
 
IR 
95 % 
1.487-1.497 
0.967-0.980 
Mixture of positional 
isomers (2-Ethyl-5/6-
ethylpyrazine), 2-5- (66 %) 
and 2-6-isomers (33%) (sum 
97 %) (EFFA, 2010a). 
14.121 
790 
2-Isopropyl-(3,5 or 6)-
methoxypyrazine 
N
N N
N
N
N
O O
O
2-Methoxy-3-isopropylpyrazine 2-Methoxy-5-isopropylpyrazine
2-Methoxy-6-isopropylpyrazine
3358 
11344 
93905-03-4 
Liquid 
C8H12ON2 
152.2 
Soluble 
Miscible 
120-125 (26hPa) 
 
IR 
97 % 
1.492-1.499 
1.010-1.022 
Mixture of positional 
isomers (2-Isopropyl-3/5/6-
methoxy), 2-3- (75-85 %); 
2-5- (15-25 %) and 2-6-
isomers (1-2 %) (sum 97 %) 
(EFFA, 2010a). 
14.123 
764 
Isopropylpyrazine 
N
N
3940 
11343 
29460-90-0 
Liquid 
C7H10N2 
122.17 
Soluble 
Miscible 
70 (26 hPa) 
 
IR 
98 % 
1.486-1.496 
0.967-0.972 
 
 
14.142 
763 
Propylpyrazine N
N  
3961 
11362 
18138-03-9 
Liquid 
C7H10N2 
122.17 
Soluble 
Miscible 
65 (16 hPa) 
 
NMR 
98 % 
1.492-1.496 
0.966-0.970 
 
 
14.144 
951 
Pyrazine 
N
N
 
4015 
11363 
290-37-9 
Solid 
C4H4N2 
80.09 
Freely soluble 
Very soluble 
115-118 
53 
IR 
98 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2: GENOTOXICITY DATA  
Table 2.1: Genotoxicity Data (in vitro / in vivo) for 41 Pyrazines (JECFA, 2002a)  
Table 2.1: Summary of Genotoxicity Data for 41 Pyrazines (JECFA, 2002a) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration *) Results Reference 
In vitro 
14.019 
774 
2,3,5-Trimethylpyrazine N
N
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.98–97 735 mg/plate Negativea (Aeschbacher et al., 
1989) 
14.020 
766 
2,5-Dimethylpyrazine N
N  
Reverse mutation S. typhimurium TA98, TA100 Not reported Negativea (Lee et al., 1994a) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1537 
12 500–200 000 mg/ 
plate 
Negativea (Stich et al., 1980) 
Mutation  S. cerevisiae D5 16 900–135 000 mg/ml Positiveb (Stich et al., 1980) 
Chromosomal aberration Chinese hamster ovary cells 2500–40 000 mg/ml Positivea (Stich et al., 1980) 
14.021 
767 
2,6-Dimethylpyrazine N
N  
Reverse mutation S. typhimurium TA100 
S. typhimurium TA 98 
S. typhimurium TA 98 
86–10 800 mg/plate 
2160–10 800 mg/plate 
86–10 800 mg/plate 
Negativea  
Positiveb  
Negativec 
(Lee et al., 1994a) 
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.54–54 000 mg/plate Negativea (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1537 
6300–100 000 mg/plate  Negativea (Stich et al., 1980) 
Mutation  S. cerevisiae D5 3300–33 800 mg/ml Positiveb (Stich et al., 1980) 
Chromosomal aberration Chinese hamster ovary cells 5000–10 000 mg/ml Positivea (Stich et al., 1980) 
14.022 
762 
Ethylpyrazine 
2-Ethylpyrazine 
N
N
 
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.97–97 200 mg/plate Negativea (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1537 
6300–100 000 mg/plate Negativea (Stich et al., 1980) 
Mutation  S. cerevisiae D5 8500–67 500 mg/ml Positiveb (Stich et al., 1980) 
Chromosomal aberration Chinese hamster ovary cells 2500–5000 mg/ml Positivea (Stich et al., 1980) 
14.024 
776 
2-Ethyl-3,5-dimethylpyrazine 
3-Ethyl-2,6-dimathylpyrazine 
N
N
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.97–97 200 mg/plate Negativea (Aeschbacher et al., 
1989) 
14.025 
788 
2,5 or 6-Methoxy-3-methylpyrazine 
(2 or 5 or 6)-Methoxy-3-methylpyrazine 
N
N O N
N
O
N
N
O
2-Methoxy-3-methylpyrazine 6-Methoxy-3-methylpyrazine
5-Methoxy-3-methylpyrazine
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538 
 3600 mg/plate  Negativea (Wild et al., 1983) 
14.027 
761 
2-Methylpyrazine N
N  
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.94–94,000 mg/plate Negativea (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100 Not reported Negativea (Lee et al., 1994a) 
Reverse mutation S. typhimurium TA 98, TA100, 
TA1537 
6300–100 000 mg/plate Negativea (Stich et al., 1980) 
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Table 2.1: Summary of Genotoxicity Data for 41 Pyrazines (JECFA, 2002a) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration *) Results Reference 
Mutation  S. cerevisiae D5 8500–67 500 mg/ml Positiveb  (Stich et al., 1980) 
Chromosomal aberration Chinese hamster ovary cells 2500–40 000 mg/ml Positivea (Stich et al., 1980) 
14.050 
765 
2,3-Dimethylpyrazine N
N
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.97–97 200 mg/plate Negativea (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100 Not reported Negativea (Lee et al., 1994a) 
14.144 
951 
Pyrazine 
N
N
 
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
0.64–64 000 mg/plate Negativea (Aeschbacher et al., 
1989) 
Reverse mutation S. typhimurium TA98, TA100 Not reported Negativea (Lee et al., 1994a) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1537 
6300–100 000 mg/plate Negativea (Stich et al., 1980) 
Mutation S. cerevisiae D5 7500–60 000 mg/ml  Positiveb (Stich et al., 1980) 
Chromosomal aberration Chinese hamster ovary cells 2500–25 000 mg/ml Positivea (Stich et al., 1980) 
In vivo 
14.025 
788 
2,5 or 6-Methoxy-3-methylpyrazine 
(2 or 5 or 6)-Methoxy-3-methylpyrazine 
N
N O N
N
O
N
N
O
2-Methoxy-3-methylpyrazine 6-Methoxy-3-methylpyraz
5-Methoxy-3-methylpyrazine
Basc mutation Drosophila melanogaster 10 mmol/L Negative (Wild et al., 1983) 
Micronucleus formation Mouse 87, 174, or 248 mg/kg 
bw 
Negative (Wild et al., 1983) 
*: Concentration should be in microgram not mg..A mistake in the JECFA monograph. 
a: With and without metabolic activation. 
b: Without metabolic activation. 
c: With metabolic activation. 
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Table 2.2: Genotoxicity Data (in vitro) EFSA / FGE.17Rev2 
Substances listed in brackets are the JECFA evaluated supporting substances in FGE.17Rev2 
Table 2.2: Summary of Genotoxicity Data (in vitro) EFSA, FGE.17Rev2 
 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(Pyrazine [14.144]) 
  
Ames test S. typhimurium 
TA98; TA100; TA102 
64000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
64000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
Not reported Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound within a large study, details are reported for positive compounds only.  
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Ames test S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538 
10000 µg/ml Negative1, 2 (Fung et al., 1988) Valid study in accordancce with OECD guideline 471. 
 
Mutation assay S. cerevisiae 
Strain D5 
60000 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
Aberration assay 
Chinese hamster 
ovary cells 
10000 µg/ml 
2500 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
Mouse lymphoma 
mutagenesis assay 
mouse lymphocytes  
L5178Y TK+/- 
10000 µg/ml Negative1 (Fung et al., 1988) Study in accordancce with former OECD guideline 476 (1983); colonies were not 
sized and results were not confirmed in a second study as requested by the OECD 
guideline in force. Therefore, chromosomal aberrations effects could not be ruled 
out.   
(2-Methylpyrazine [14.027]) Ames test S. typhimurium 
TA98; TA100; TA102 
94000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
94000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
Not reported Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound of a large study, details are reported for positive compounds only. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
67500 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
Aberration assay 
Chinese hamster 
ovary cells 
40000 µg/ml 
20000 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(Ethylpyrazine [14.022]) Ames test S. typhimurium 
TA98; TA100; TA102 
97200 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97200 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
67500 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
Aberration assay 
Chinese hamster 
ovary cells 
5000 µg/ml 
2500 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(2,3-Dimethylpyrazine [14.050]) Ames test S. typhimurium 
TA98; TA100; TA102 
97200 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97200 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains. only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
NR Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound within a large study, details are reported for positive compounds only. 
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Table 2.2: Summary of Genotoxicity Data (in vitro) EFSA, FGE.17Rev2 
 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(2,5-Dimethylpyrazine [14.020]) Ames test S. typhimurium 
TA98; TA100; TA102 
97200 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97200 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
Not reported Negative1 (Lee et al., 1994a) Report of insufficient quality because test concentrations are not given. Reference 
compound of a large study, details are reported for positive compounds only. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
200000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
135500 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
aberration assay 
Chinese hamster 
ovary cells 
40000 µg/ml 
20000 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(2,6-Dimethylpyrazine [14.021]) Ames test S. typhimurium 
TA98; TA100; TA102 
54000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
54000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
Ames test S. typhimurium 
TA98; TA100 
10800 Negative4 (Lee et al., 1994a) Well conducted study, valid although not in accordance with OECD guideline 
471: two S. typhimurium strains only. 
Ames test S. typhimurium 
TA98; TA100; TA1537 
100000 µg/plate Negative1 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Mutation assay S. cerevisiae 
Strain D5 
33800 µg/ml Positive3 (Stich et al., 1980) Study with strong limitations with results of limited value. 
Chromosomal 
aberration assay 
Chinese hamster 
ovary cells 
10000 µg/ml 
2500 µg/ml 
Positive1 
Positive1 
(Stich et al., 1980) Study with strong limitations with results of limited value. 
(2,3-Diethylpyrazine [14.005]) Ames test S. typhimurium 
TA98; TA100; TA102 
109000 µg/plate Negative1 (Aeschbacher et al., 
1989) 
109000 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only, dose range but not individual doses reported. 
(2,3,5-Trimethylpyrazine [14.019]) Ames test S. typhimurium 
TA98; TA100; TA102 
97735 µg/plate Negative1 (Aeschbacher et al., 
1989) 
97735 µg/plate: highest non-bactericidal dose. Well conducted study, valid 
although not in accordance with OECD guideline 471: three S. typhimurium 
strains only. 
((2,5 or 6)-Methoxy-3- 
methylpyrazine [14.025]) 
Ames test S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538 
3600 µg/plate Negative1 (Wild et al., 1983) Well conducted study, valid although not in accordance with OECD guideline 
471:  test concentrations not reported. 
(Pyrazinylethanethiol [14.031]) Ames test S. typhimurium 
TA97; TA98; TA100; TA1535 
NR Negative1 (Zeiger and Margolin, 
2000) 
Well conducted study, valid although not in accordance with OECD guideline 
471: report does not give test concentrations, four test concentarions. 
Quinoxaline [14.147] Ames test S. typhimurium 
TA98; TA100 
NR Negative3 (Beutin et al., 1981) TA98 ; TA100: results presented in detail, without metabolic activation.  
TA1535,TA1537,TA1538: results incl. metabolic activation are mentioned in text 
(negative), but no data given. Not in accordance with OECD guideline 471.  
Ames test S. typhimurium 
TA98; TA100; TA102 
0.35 mmol Negative3, 5 (Aeschbacher et al., 
1989) 
0.35 mmol: highest non-bactericdial dose. Well conducted study, valid although 
not in accordance with OECD guideline 471: three S. typhimurium strains only, 
dose range but not individual doses reported. 
Modified Ames 
test 
S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538; 
G46; C3076; D3052 
E. coli 
WP2; WP2uvrA- 
NR Negative3 (McMahon et al., 1979) Review, of limited value (concentrations tested not reported).  
Ames test 
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100; TA1535; TA1537; TA1538 
10000 µg/plate Negative3 (San, 1995) Valid study in accordancce with OECD guideline 471. 
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Table 2.2: Summary of Genotoxicity Data (in vitro) EFSA, FGE.17Rev2 
 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
DNA Polymerase 
deficiency assay 
E. coli NR Negative3 (Rosenkranz & Leifer, 
1980) 
Review, of limited value (concentrations tested not reported; without metabolic 
activation). 
SOS 
Chromosome test 
E. coli 
PQ37 
NR Negative1 (Beutin et al., 1981)  
Mouse lymphoma 
mutagenesis assay 
L5178Y TK+/- 
mouse lymphocytes 
(with S9) 20 – 
250 
(without S9) 100 
– 1500 microg/ml 
 
Positive6 
Weakly 
Positive3 
(National Cancer 
Institute, 1998) 
Valid study in accordancce with OECD guideline 476.  
 
2-Methylquinoxaline [14.139] Ames test S. typhimurium 
TA98; TA100 
500 µg/plate Positive1 (Hashimoto et al., 1979) Well conducted study, valid although not in accordance with OECD guideline 
471: two S. typhimurium strains only, highest dose but not individual doses 
reported. 
Positive only in TA98 and T100 with metabolic activation.  
Ames test S. typhimurium 
TA98; TA100; TA102 
0.007 - 700 
µmol/plate 
(equal to 0.001 – 
100 mg/plate) 
Negative1, 7 (Aeschbacher et al., 
1989) 
0.7 mmol: highest non-bactericidal dose. Well conducted study (valid), but not in 
accordance with OECD guideline 471: three S. typhimurium strains only, dose 
range but not individual doses reported. 
2,3-Dimethylquinoxaline [14.108] Ames test S. typhimurium 
TA98; TA100; TA1535; 
2500 µg/plate Negative6 (Anderson and Styles, 
1978) 
Well conducted study, valid although not in accordance with OECD guideline 
471 (with S9 metabolic activation only). 
Ames test S. typhimurium 
TA100 
NR Negative6 (Epler et al., 1978) Review, no detailed information on test conditions incl.concentration. Authors 
pointed out the unanswered question whether the testing of negative compounds 
can sensibly be terminated (in 1978).  
 Ames test S. typhimurium 
TA98; TA100 
NR Negative1 (Hashimoto et al., 1979) Validity cannot be evaluated. Concentrations not reported. Results not reported in 
detail. 
(5-Methylquinoxaline [14.028]) Reverse mutation S. typhimurium TA 98, TA100, TA1535, 
TA1537 and E.coli strain WP2 uvrA 
Up to 5000 
microgram/plate 
Negative1 (Ogura & Wakamatsu, 
2004) 
Valid. GLP-study in compliance with OECD 471 (except that no justification was 
provided for the use of duplicate instead of triplicate plating). 
Chromosomal 
aberration assay 
Chinese hamster lung-derived CHL/IU 
cells 
320, 480, 720 
microgram/ml 
72, 228, 720 
microgram/ml 
Negative3 
 
Positive6 
(Ajimu & Kawaguchi, 
2004a) 
Valid. GLP-study mainly in compliance with OECD 473 (duration of exposure 
not clearly reported). The authors noted in the discussion section that cytotoxicty 
was observed in the form of decreased cell viability and reproductive rate. 
However, it is not clear if one or two parameters for cytotoxicity were measured. 
The percentage of “cell productivity” (the cell number was measured and 
expressed as relative growth rate compared to negative control) was reported. 
According to the authors, there was a clear evidence of cytotoxicty in the form of 
decreased cell viability and reproductive rate at concentrations where 
chromosomal aberrations were observed. However, the results presented in tables 
demonstrate that 30 and 66 % of cell with chromosomal aberrations were induced 
at the limit of exessive cytotoxicty (54 and 46% of relative growth) in the 
preliminary test (in which 50 cells per slide were scored) at 180 and 360 µg/mL in 
the presence of S9, respectively. In the main test, the percentage of cells with 
chromosomal aberrations in the presence of S9 was 2.0, 2.5, 6.5 and 57.5 at 0, 72, 
228 and 720 µg/mL, respectively, which was accompanied by 100, 90, 85 and 
46% relative growth, respectively. 
NR: Not reported. 
1 With and without S9 metabolic activation.  
2 Metabolic activation was provided with both rat and hamster liver S9 mix.  
3 Without S9 metabolic activation.  
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4 Results were negative in TA100 with and without S9 metabolic activation; however, in TA98 the results were negative and positive with and without S9 metabolic activation, respectively.  
5 Results were negative in TA100 with and without S9 metabolic activation. Weak results were noted in TA98 and TA102 with S9 metabolic activation. These changes may be related to the heat production products of the Maillard reaction in the 
presence of creatinine.  
6 With S9 metabolic activation.  
7 Weak results were noted in all strains with S9 metabolic activation. (the number of revertants was increased up to 1.3-fold compared to control). According to the authors (Aeschbacher et al., 1989), these changes may be related to the heat 
production products of the Maillard reaction in the presence of creatinine.  
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Table 2.3: Genotoxicity Data (in vivo) EFSA / FGE.17Rev2 
Substances listed in brackets are JECFA-evaluated supporting substances in FGE.17Rev2. 
Table 2.3: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
((2,5 or 6)-Methoxy-3- methylpyrazine 
[14.025]) 
Basc test D. 
melangaster 
 10 mM Negative (Wild et al., 1983) Limited relevance for risk assessment as the test is not in a mammalian 
system and the test is not used routinely.  
Micronucleus assay Mouse  248 mg/kg Negative (Wild et al., 1983) Study design does not meet the criteria of current guidelines (PCE/NCE 
ratio was not reported, thus it is not clear if the test substance reached 
the bone marrow). Not in accordance with OECD guideline 474 
(1983/1997). 
Quinoxaline [14.147] Sperm head abnormality 
test 
Mouse I.P 2500 mg/kg  Negative (Topham, 1980) Sperm head abnormality test does not make use of a genetic endpoint. 
(5-Methylquinoxaline [14.028]) Micronucleus assay Mouse Gavage 125, 250 and 
500 mg/kg/day 
Negative (Ajimu & Kawaguchi, 
2004b) 
Valid. GLP-study mainly in compliance with OECD 474 (only 5 male 
mice per group instead of 5 males and 5 females),  
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
Table 3.1: Summary of Safety Evaluation of Pyrazine and 40 Derivatives (JECFA, 2003a) 
Table 3.1: Summary of Safety Evaluation of JECFA-Evaluated Pyrazine Derivatives (JECFA, 2003a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
14.005 
771 
2,3-Diethylpyrazine N
N  
1.6 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.006 
768 
2-Ethyl-3-methylpyrazine N
N  
72 
9 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.017 
770 
2-Ethyl-5-methylpyrazine N
N  
4.0 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.018 
780 
2,3,5,6-Tetramethylpyrazine 
N
N
 
6.7 
19 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.019 
774 
2,3,5-Trimethylpyrazine N
N  
100 
46 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.020 
766 
2,5-Dimethylpyrazine N
N  
19 
8 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.021 
767 
2,6-Dimethylpyrazine N
N  
1.3 
2 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.022 
762 
Ethylpyrazine 
N
N
 
2.2 
6 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.024 
776 
2-Ethyl-3,5-dimethylpyrazine N
N  
1.2 
0.3 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 3.1: Summary of Safety Evaluation of JECFA-Evaluated Pyrazine Derivatives (JECFA, 2003a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
14.025 
788 
2,5 or 6-Methoxy-3-methylpyrazine 
N
N O N
N
O
N
N
O
2-Methoxy-3-methylpyrazine 6-Methoxy-3-methylpyrazine
5-Methoxy-3-methylpyrazine
2.2 
15 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.026 
772 
2-Isopropyl-5-methylpyrazine 
N
N
0.024 
0.4 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.027 
761 
2-Methylpyrazine N
N  
17 
7 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.032 
784 
Acetylpyrazine 
N
N
O 12 
120 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.037 
781 
6,7-Dihydro-5-methyl-5H-
cyclopentapyrazine 
N
N
 
3.9 
4 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.043 
792 
2-Isobutyl-3-methoxypyrazine 
N
N
O
1.6 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.044 
773 
2-Isobutyl-3-methylpyrazine N
N  
0.037 
0.01 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.049 
785 
2-Acetyl-3-ethylpyrazine 
N
N
O 0.73 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.050 
765 
2,3-Dimethylpyrazine N
N  
14 
4 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.054 
787 
Methoxypyrazine N
N
O
 
3.0 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 3.1: Summary of Safety Evaluation of JECFA-Evaluated Pyrazine Derivatives (JECFA, 2003a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
14.055 
786 
2-Acetyl-3,5-dimethylpyrazine 
N
N
O
N
N
O 0.97 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.056 
777 
2,3-Diethyl-5-methylpyrazine 
N
N
 
0.11 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.062 
791 
2-(sec-Butyl)-3-methoxypyrazine N
N
O 0.85 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.077 
789 
2-Ethyl-(3,5 or 6)-methoxypyrazine 
(85%) and 2-Methyl-(3,5 or 6)-
methoxypyrazine (13%) 
N
N
O
N
N
O
(85%) (15%)
1.3 
1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.082 
950 
2-Acetyl-3-methylpyrazine 
N
N
O 0.1 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.095 
779 
3,5-Diethyl-2-methylpyrazine 
N
N
 
0.012 
0.01 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.096 
778 
2,5-Diethyl-3-methylpyrazine 
N
N
 
0.012 
0.01 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.098 
782 
6,7-Dihydro-2,3-dimethyl-5H-
cyclopentapyrazine 
N
N
 
0.012 
0.01 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
CASrn in Register refers to 
6,7-dihydro-3,5-dimethyl-
5H-cyclopentapyrazine. 
CASrn to be changed. 
14.100 
775 
3,(5- or 6-)-Dimethyl-2-
ethylpyrazine 
N
N
N
N
2-Ethyl-3,6-dimethylpyrazine2-Ethyl-3,5-dimethylpyrazine  
38 
9 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.114 
769 
2-Ethyl-6-methylpyrazine 
N
N 0.37 
0.4 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
No safety concern at the 
estimated level of intake 
based on the MSDI 
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Table 3.1: Summary of Safety Evaluation of JECFA-Evaluated Pyrazine Derivatives (JECFA, 2003a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
approach approach. 
14.121 
790 
2-Isopropyl-(3,5 or 6)-
methoxypyrazine 
N
N N
N
N
N
O O
O
2-Methoxy-3-isopropylpyrazine 2-Methoxy-5-isopropylpyr
2-Methoxy-6-isopropylpyrazine
0.0012 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.123 
764 
Isopropylpyrazine 
N
N
0.12 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.142 
763 
Propylpyrazine N
N  
0.12 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.015 
952 
5,6,7,8-Tetrahydroquinoxaline N
N  
8 
ND 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.028 
798 
5-Methylquinoxaline 
N
N
 
22 
1 
Class III 
A3: Intake below threshold 
4) The Panel concluded based 
on additional data that the 
genotoxicity alert can be 
ruled out. No safety 
concern at the estimated 
level of intake based on the 
MSDI approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.031 
795 
Pyrazineethanethiol 
N
N SH
 
0.13 
1 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.034 
796 
Pyrazinyl methyl sulfide 
N
N S
 
0.0061 
0.01 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.035 
797 
2-Methyl-3,5 or 6-
methylthiopyrazine 
N
N
N
N
N
N
S S
S
3-Methylthio-2-methylpyrazine 5-Methylthio-2-methylpyra
6-Methylthio-2-methylpyrazine
6.3 
13 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 3.1: Summary of Safety Evaluation of JECFA-Evaluated Pyrazine Derivatives (JECFA, 2003a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
14.053 
794 
Mercaptomethylpyrazine N
N
SH
 
0.012 
0.01 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.067 
793 
2-Methyl-3,5 or 6-ethoxypyrazine N
N
N
N
N
N
O O
O
2-Methyl-3-ethoxypyrazine 2-Methyl-5-ethoxypyrazine
2-Methyl-6-ethoxypyrazine
0.055 
0.01 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.069 
783 
Cyclohexylmethylpyrazine N
N  
0.012 
0.01 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
14.144 
951 
Pyrazine 
N
N
 
0.024 
0.2 
Class III 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
 
ND: not determined. 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (EFSA / FGE.17Rev2) 
Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1)  
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound  
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
14.081 
 
5-Acetyl-2,3-dimethylpyrazine 
N
N
O 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.083 
 
2-Acetyl-5-ethylpyrazine 
N
N
O 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.084 
 
2-Acetyl-5-methylpyrazine 
N
N
O 0.0024 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.086 
 
2-Acetyl-6-ethylpyrazine 
N
N
O 0.0061 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.087 
 
2-Acetyl-6-methylpyrazine 
N
N
O 0.028 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.091 
 
2-Butyl-3-methylpyrazine 
N
N 0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.097 
 
2,5-Diethylpyrazine 
N
N 0.024 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.099 
 
6,7-Dihydro-5,7-dimethyl-5H-
cyclopentapyrazine 
N
N
0.032 
 
Class II 
A3: Intake below threshold 
4) 7)  
14.101 
 
2,5-Dimethyl-3-
isopropylpyrazine 
N
N 0.018 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1)  
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound  
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
14.102 
 
5,6-
Dimethyldihydrocyclopentapyraz
ine 
N
N
N
N 0.024 
 
Class II 
A3: Intake below threshold 
4) 7)  
14.113 
 
5-Ethyl-6,7-dihydro-5H-
cyclopentapyrazine 
N
N 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.127 
 
2-Methoxy-3-propylpyrazine 
N
N O 0.061 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.129 
 
2-Methyl-3-propylpyrazine 
N
N 0.011 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.148 
 
5,6,7,8-Tetrahydro-5-
methylquinoxaline 
N
N 0.0073 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.161 
 
6,7-Dihydro-2,5-dimethyl-5H-
cyclopentapyrazine 
N
N 0.011 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.052 
 
Isopropenylpyrazine 
N
N
0.012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
14.051 
 
2,5 or 6-Methoxy-3-
ethylpyrazine 
N
N
O
 
 
Class II 
No evaluation 
   
14.108 
 
2,3-Dimethylquinoxaline 
N
N 0.049 
 
Class III 
A3: Intake below threshold 
4) 6)  
14.122 
 
2-Isopropyl-3-
methylthiopyrazine 
N
N
S
0.061 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.139 
 
2-Methylquinoxaline 
N
N 0.12 
 
Class III 
A3: Intake below threshold 
4) 6)  
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1)  
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound  
[4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
14.147 
 
Quinoxaline 
N
N 0.12 
 
Class III 
No evaluation 
  a) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practise 
ID  Identity 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MNPCE Micronucleated polychromatic erythrocytes 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
PCE  Polychromatic erythrocyte 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
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WHO  World Health Organisation 
